News

Preliminary data suggests that the combination is well tolerated, with a toxicity profile similar to known toxicities of each agent alone. The combination therapy has also shown promising

It also showed signs of activity in patients with non-small cell lung, ovarian, breast, prostate, pancreatic, head and neck and colon cancer, according to Kosan. The Phase I

In a separate suit against Lichtwer Pharma, one of Nutrinova’s customers, a similar judgment was announced. The first suit involves Lonza’s German sale and use of a fatty

Novo Nordisk expects to launch Levemir (insulin detemir) in Japan in its prefilled FlexPen device and in Penfill for its NovoPen injection systems before the end of 2007.

The Japanese Ministry of Health approval means that lung cancer patients in Japan will now have a new treatment option that has been demonstrated to increase overall survival

The estimated value of the combined company is approximately $115 million, based on the closing price of Avant’s stock on October 19, 2007. The all-stock transaction, approved by

Sequella’s lead drug, SQ109, shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant tuberculosis (TB) bacteria, including XDR-TB, according to the company. Furthermore, SQ109 synergizes

Clinical trials have demonstrated Voltaren Gel to be highly effective in treating osteoarthritis pain in the hands and knees, which are the body’s most commonly affected joints, according

The research effort, which will be centered on tamoxifen, is the latest in a rapidly growing field of studies linking individual genetics to the safety and efficacy of